Anaemia and its functional consequences in cancer patients: Current challenges in management and prospects for improving therapy

British Journal of Cancer

Volumn 84, Issue SUPPL. 1, 2001, Pages 31-37

  Demetri, G D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anaemia; Cancer; Chemotherapy; Darbepoetin alfa; Radiotherapy; Recombinant human erythropoietin

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CARBOHYDRATE; DARBEPOIETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERRITIN; HEMOGLOBIN; IRON; NEOPTERIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SIALIC ACID; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ALLERGY; ANEMIA; ARTICLE; CANCER; CLINICAL TRIAL; COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; ERYTHROCYTE TRANSFUSION; FEVER; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; INFECTION; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0034997122     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1750     Document Type: Article

References (53)

1. Abels R (1993) Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A: S2-8
2. Abels RI (1992) Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 19: 29-35
3. Beguin Y (1996) Erythropoietin and the anemia of cancer. Acta Clin Belg 51: 36-52
4. Beguin Y (1998) Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 25: 27-34
5. Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S and Catalano G (1994) Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 12: 1058-1062
6. Case DC. Jr., Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, Jones SE, Keller AM, Kugler JW and Nichols CR (1993) Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85: 801-806
7. Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34: 13-19
8. Cleeland CS, Demetri GD, Glaspy J, Cella DF, Portenoy RK, Cremieux PY and Itri L (1999) Identifying hemoglobin level for optimal quality of life: results of an incremental analysis. Proc Am Soc Clin Oncol 18; 574a (abstract 2215)
9. Coiffier B (1998) Retrospective analysis of hematological parameters and transfusion requirements in non-platinum chemotherapy-treated patients. Proc Am Soc Clin Oncol 17: 90a (abstract 346)
10. Cremieux PY, Barrett B, Anderson K and Slavin MB (2000) Cost of outpatient blood transfusion in cancer patients, J Clin Oncol 18; 2755-2761
11. Curt GA (2000) The impact of fatigue on patients with cancer: Overview of FATIGUE 1 and 2. Oncologist 5 Suppl 2: 9-12
12. Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK and Vogelzang NJ (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. The Oncologist 5: 353-360
13. Dalton JD. Bailey NP, Barrett-Lee PJ and O'Brien MER (1998) Multicenter UK audit of anemia in patients receiving cytotoxic chemotherapy. Proc Am Soc Clin Oncol 17: 418a (abstract 1611)
14. Demetri GD. Kris M, Wade J, Degos L and Cella D (1998) for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16: 3412-3425
15. Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, Brugere J, Point D, Giraud P and Cosset JM (1996) Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 201: 553-8
16. Egrie JC, Dwyer E, Lykos M, Hitz A and Browne JK (1997) Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO). Blood 90:56a (abstract 243)
17. Estrin JT, Schocket L, Kregenow R and Henry DH (1999) A retrospective review of blood transfusions in cancer patients with anemia. The Oncologist 4: 318-324
18. Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ, Jr. and Coia LR (1995) Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 13: 2077-2083
19. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, Chapman W, Levin W. Manchul L, Keane TJ and Hill RP (1998) Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48: 149-156
20. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S and Vadhan-Raj S (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218-34
21. Glaspy J and Cavill I (1999) Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology 13: 461-473
22. Glaspy J and Harper P (2000) Discussion. Semin Oncol 27: 16-17
23. Glaspy J, Meza L, Smith R, Fleishman A, Mendes E and Colowick A (2000) Open-label, phase I/II dose escalation study of ARANESP in patients with chronic anemia of cancer. Blood 96: 154b (abstract 4370)
24. Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Saven A, Hynes H, Boccia R, O'Byrne J and Colowick AB (2001) A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 84 (Supp 1): 17-23
25. Goodnough LT, Brecher ME, Kanter MH and AuBuchon JP (1999) Transfusion medicine. First of two parts: blood transfusion. N Engl J Med 340: 438-447
26. Grogan M, Thomas GM, Melamed I, Wong FLW, Pearcey RG, Joseph PK, Portelance L. Crook J and Jones KD (1999) The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528-1536
27. Groopman JE and Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616-1634
28. Harrison LB, Shasha D. White C and Ramdeen B (2000) Radiotherapy-associated anemia: the scope of the problem. Oncologist 5: 1-7
29. Heatherington AC, Schuller J and Mercer AJ (2001) Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 84 (Supp 1): 11-16
30. Henry DH and Abels RI (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 21: 21-28
31. Khayat D (2000) Is anemia a problem for European cancer patients and treating oncologists? Semin Oncol 17: 9-11
32. Kotasek D, Berg R, Poulsen E and Colowick A (2000) Randomized, double-blind, placebo controlled, phase I/II dose finding study of ARANESP administered once every three weeks in solid tumor patients. Blood 96: 294a (abstract 1268)
33. Lawless G, Wilson-Royalty M and Meyers J (2000) Epoetin alfa practice pattern usage in community practice sites. Blood 96: 390b (abstract 5446)
34. Leitgeb C, Pecherstorfer M, Fritz E and Ludwig H (1994) Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 73: 2535-2542
35. Ludwig H (1999) Epoetin in cancer-related anaemia. Nephrol Dial Transplant 14: 85-92
36. Ludwig H and Fritz E (1998a) Anemia in cancer patients. Semin Oncol 25: 2-6
37. Ludwig H and Fritz E (1998b) Anemia in cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol 25: 35-38
38. Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H and Schuster J (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84: 1056-63
39. Ludwig H, Sundal E, Pecherstorfer M, Leitgeb C, Bauernhofer T, Beinhauer A, Samonigg H, Kappeler AW and Fritz E (1995) Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 76: 2319-2329
40. Macdougall IC (1998) Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia. J Am Soc Nephrol 9: 258a-259a (abstract A1317)
41. Macdougall IC (2000) Novel erythropoiesis stimulating protein. Semin Nephrol 20: 375-381
42. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J and Egrie J (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392-2395
43. Mercadante S, Gebbia V, Marrazzo A and Filosti S (2000) Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 26: 303-311
44. Ortho Biotech (1999) Epoetin alfa prescribing information: Raritan: New Jersey
45. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, Chevreau C, Sebban C, Bachelot T. Biron P and Blay JY (1999) Risk model for severe anemia requiring red blood cell transformation after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol 17: 2840-2846
46. Smith RE Jr, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, Brosman S, Bukowski R, Murdock M, Rarick M, Saven A, Colowick AB, Fleishman A, Gayko U and Glaspy J (2001) Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 84 (Supp 1): 24-30
47. Stone P, Richardson A, Ream E, Smith AG, Kerr DJ and Kearney N (2000) Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multicentre patient survey. Cancer Fatigue Forum. Ann Oncol 11: 971-5
48. Throuvalas NA, Antonadou D, Boufi M, Lavey R and Malamos N (2000) Erythropoietin decreases transfusion requirements during radiochemotherapy. Proc Am Soc Clin Oncol 19: 394a (abstract 1558)
49. TM in oncology patients undergoing multicycle chemotherapy. Blood 96: 156b (abstract 4379)
50. Vanrenterghem Y, Barany P and Mann J (1999) Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once weekly or once every other week. J Am Soc Nephrol 10: 270A (abstract A1365)
51. Vogelzang NJ, Breitbart W. Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK and Coalition TF (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol 34: 4-12
52. Warde P, O'Sullivan B, Bristow RG, Panzarella T, Keane TJ, Guilane PJ, Witterick IP, Payne D, Liu FF, McLean M, Waldron J and Cummings BJ (1998) T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 41: 347-353
53. Yellen SB, Cella DF, Webster K, Blendowski C and Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13: 63-74